跳至主要内容
临床试验/NCT02475616
NCT02475616终止1 期

A Randomized, Double-blind, Single Ascending Oral Dose Study To Evaluate Safety, Tolerability And Pharmacokinetics Of PCO371 In Healthy Volunteers

Chugai Pharmaceutical1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2015年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
入组人数
64
试验地点
1
主要终点
Safety as assessed by pulse rate

研究概览

简要总结

This is a single-center, placebo-controlled, randomized, double-blind, dose-escalation study to evaluate safety, tolerability, and PK of a single oral (PO) administration of PCO371 in healthy adult males.

Caucasian and Japanese subjects will be randomized to receive either PCO371 or placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male volunteers aged 18 to 45 years.
  • Caucasian(BMI 18-30 mg/kg2) or first generation japanese(BMI 18-25kg/m2)
  • Able and willing to abide by the protocol

排除标准

  • Evidence of any medical condition that could affect renal, hepatic, or cardiopulmonary functions.

研究组 & 干预措施

PCO371

Experimental

Single oral dose of PCO371

干预措施: PCO371 (Drug)

Placebo Comparator

Placebo Comparator

Single oral dose of placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Safety as assessed by pulse rate

时间窗: 15days or 22days

Safety as assessed by adverse events

时间窗: 15days or 22days

Safety as assessed by temperature

时间窗: 15days or 22days

Safety as assessed by systolic blood pressure, diastolic blood pressure

时间窗: 15days or 22days

Safety assessed by physical findings examinations, including weight

时间窗: 15days or 22days

Safety as assessed by Laboratory test values

时间窗: 15days or 22days

Laboratory tests include hematology, biochemistry, urine analysis and coagulation

Safety as assessed by ECGs

时间窗: 15days or 22days

Plasma concentrations and PK parameters (AUC, Cmax, Tmax, total clearance, volume of distribution and T1/2) of PCO371 in healthy male volunteers

时间窗: 15days or 22days

Urine concentrations and PK parameters (cumulative excretion and renal clearance) of PCO371

时间窗: 15days or 22days

次要结局

  • The Urinary excretion of Ca, phosphate, magnesium, protein, sodium, potassium, chloride, and cAMP of PCO371(15days)
  • The Nephrogenous cAMP of PCO371(15days)
  • The Time profile of serum/plasma concentrations in albumin-corrected total calcium (Ca); 25-hydroxy vitamin D (vit D), 1,25-dihydroxy vit D, and 24,25-dihydroxy vit D; phosphate; magnesium; and cAMP of PCO371(15days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Single Ascending Dose Study of PCO371 in Healthy... | 临床试验